Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Mar 31, 2026 5:22pm EDT
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement Mar 23, 2026 7:30am EDT
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical Mar 19, 2026 7:30am EDT
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders Feb 24, 2026 7:00am EST
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC Dec 19, 2025 5:05pm EST
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations Dec 06, 2025 8:00am EST
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical Nov 19, 2025 1:22am EST
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting Nov 03, 2025 9:00am EST
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML Oct 16, 2025 7:30am EDT
